Lung Cancer

A head-to-head trial of the PD-1 inhibitors dostarlimab and pembrolizumab, each in combination with chemotherapy, met its primary endpoint of objective response rate among patients with metastatic nonsquamous non-small cell lung cancer.

The FDA granted fast track designation to sapanisertib for treatment of certain patients with non-small cell lung cancer.

This year’s European Society for Medical Oncology Congress featured potentially practice-changing research in kidney cancer, cutaneous squamous cell carcinoma, lung cancer and melanoma.

The FDA Oncologic Drugs Advisory Committee on Thursday voted against questions regarding the benefits vs. risks of two cancer treatments for which new drug applications have been filed.

The FDA granted regular approval to selpercatinib for treatment of certain patients with non-small cell lung cancer.

President Joe Biden recently announced Renee WegrzynPhD, as the inaugural director of the Advanced Research Projects Agency for Health.

Sotorasib significantly extended PFS compared with standard-of-care docetaxel as second-line therapy for patients with KRASG12C-mutated non-small cell lung cancer, data from the randomized phase 3 CodeBreak 200 trial showed.

For a while now, I have wanted to write about Sarah Hallberg, DO, who died in March. I was not sure how best to tell the story about this champion whom I was blessed to have met in person.

In this edition, germline testing ‘should be considered’ for all patients with lung cancer; phase 3 trial of canakinumab misses endpoint; sexual dysfunction common among women with lung cancer, and more.

Exposure to increased concentrations of airborne particulate matter appeared associated with increased risk for EGFR-mutated non-small cell lung cancer among never-smokers, according to study results presented at ESMO Congress.